Cargando…
Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular ass...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167993/ https://www.ncbi.nlm.nih.gov/pubmed/35677686 http://dx.doi.org/10.3389/fcvm.2022.883669 |
_version_ | 1784720900965269504 |
---|---|
author | Martínez-Sellés, Manuel Grodzicki, Tomasz |
author_facet | Martínez-Sellés, Manuel Grodzicki, Tomasz |
author_sort | Martínez-Sellés, Manuel |
collection | PubMed |
description | Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular assist device and are in need of palliative care. The adjustment of cardiovascular drugs is frequently needed in these patients. The shift in emphasis from life-prolonging to symptomatic treatments should be a progressive one. We establish a series of recommendations with the aim of adjusting drugs in these patients, in order to adapt treatment to the needs and wishes of each patient. This is frequently a difficult process for patients and professionals, as drug discontinuing needs to balance treatment benefit with the psychological adaption to having a terminal illness. We encourage the use of validated assessment tools to assess prognosis and to use this information to take clinical decisions regarding drug withdrawal and therapeutic changes. The golden rule is to stop drugs that are harmful or non-essential and to continue the ones that provide symptomatic improvement. |
format | Online Article Text |
id | pubmed-9167993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91679932022-06-07 Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review Martínez-Sellés, Manuel Grodzicki, Tomasz Front Cardiovasc Med Cardiovascular Medicine Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular assist device and are in need of palliative care. The adjustment of cardiovascular drugs is frequently needed in these patients. The shift in emphasis from life-prolonging to symptomatic treatments should be a progressive one. We establish a series of recommendations with the aim of adjusting drugs in these patients, in order to adapt treatment to the needs and wishes of each patient. This is frequently a difficult process for patients and professionals, as drug discontinuing needs to balance treatment benefit with the psychological adaption to having a terminal illness. We encourage the use of validated assessment tools to assess prognosis and to use this information to take clinical decisions regarding drug withdrawal and therapeutic changes. The golden rule is to stop drugs that are harmful or non-essential and to continue the ones that provide symptomatic improvement. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9167993/ /pubmed/35677686 http://dx.doi.org/10.3389/fcvm.2022.883669 Text en Copyright © 2022 Martínez-Sellés and Grodzicki. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Martínez-Sellés, Manuel Grodzicki, Tomasz Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title | Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title_full | Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title_fullStr | Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title_full_unstemmed | Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title_short | Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review |
title_sort | modification of cardiovascular drugs in advanced heart failure: a narrative review |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167993/ https://www.ncbi.nlm.nih.gov/pubmed/35677686 http://dx.doi.org/10.3389/fcvm.2022.883669 |
work_keys_str_mv | AT martinezsellesmanuel modificationofcardiovasculardrugsinadvancedheartfailureanarrativereview AT grodzickitomasz modificationofcardiovasculardrugsinadvancedheartfailureanarrativereview |